36 results about "Cancer surgery" patented technology

The invention provides an application of mitoxantrone and salt thereof as a lymph tracer (such as hydrochloric acid mitoxantrone, oxalic acid mitoxantrone, sulfuric acid mitoxantrone, phosphoric acid mitoxantrone, acetic acid mitoxantrone, citric acid mitoxantrone and the like). The mitoxantrone and salt thereof can be used for preparing injection, powder injection, emulsion, liposome, nanoparticle, microballoon and the like. The mitoxantrone and salt thereof not only can be used for killing malignant tumor cells, but also the blue dye feature can be used as the lymph tracer applied to lymphadenectomy in cancer operative treatment, which is suitable for treating stomach cancer, breast cancer, intestinal cancer, cervical carcinoma, testis cancer and the like.

The invention provides a medicine for remedying cancer, in particular to a medicine for remedying various cancers after surgery. The medicine is characterized in that No. I recipe takes radix rehmanniae, red peony root, bletilla, Szechwan lovage rhizome, wine-madder, salvia, panpax notoginseng, dandelion, APN, rhodiola himalensis, raw radix astragali, angelica, wolfberry fruit, chinese yam, radix pseudostell, membrane of chicken gizzard, asparagus, trichosanthin, hawthorn and so on as raw materials; No. II recipe takes vinegar leaching and frying turtle shell, dried lacquer, duchesnea indica, citrus aurantium, earth frying atractylodes, areca nut, mythic fungus, dodder, sang, raw ochre, pubescent holly, honeysuckleand so on as raw materials; No. III recipe takes sang, liriope, liquorices, cinnamon, herba cistanches, wolfberry fruit and so on as raw materials. The recipes are separately made into decoction in proportion. The medicine uses the comprehensive effect of each medicine to remedy various cancers that have been processed with surgery. The medicine can remove blood heat, influence blood, active blood without randomly influencing, stop blood, eliminate blood stasis, produce new blood and drain deteriorated blood without harm to new blood. The clinical treatment shows that the medicine has significant efficacy.

The present invention relates generally to the field of fluorescent dyes as a system useful for surgery imaging. More particularly, the present invention relates to systems, methods and kits for exciting fluorescent, phosphorescent or luminescent molecules with light from a light source and detecting the relative fluorescent, phosphorescent, or luminescent light intensity emitted from the fluorescent, phosphorescent, or luminescent molecule. Such systems may be applied as mapping agents for various surgical techniques, such as for cancer surgeries and biopsies.

The present invention relates to a novel system for predicting a prognosis capable of predicting the prognosis of locally advanced gastric cancer, and more specifically, capable of predicting a clinical result after a resection during gastric cancer surgery through gene set enrichment comparative analysis.

The present invention relates to an auxiliary evaluation system and method for prognosis and chemotherapy benefit of gastric cancer based on enhanced CT imaging omics. A system and method of that present invention include extracting 19 image texture and morphological characteristic data of gastric cancer focus areas on enhanced CT portal vein phase images of gastric cancer objects, calculating gastric cancer imaging omics score GC Rad-score of each object, and extracting the image texture and morphological characteristic data of the gastric cancer focus areas on the enhanced CT portal vein phase images of the gastric cancer objects. Score, according to the score, predicts the prognosis and chemotherapy benefit after tumor resection and provides credible predictive and analytical results for specific individuals. The system and method of the invention are based on GC Rad-score score can be used to evaluate the prognosis and chemotherapy benefit after gastric cancer surgery. The procedure is simple, intuitive and easy to repeat. The system and method of the invention can evaluate the postoperative prognosis and chemotherapy benefit of gastric cancer, and better assist doctors to formulate treatment and follow-up plan.

Provided is a device capable of determining whether or not cancer has metastasized to a sentinel lymph node, such as the axillary lymph node, thickly covered with fat, safely and in a simple manner without confirmation by biopsy or extirpation. Fluorescence generated in a sentinel lymph node upon the excitation of protoporphyrin (a photosensitizing substance) derived from 5-ALA administered to a subject can be detected by passing a hollow tube, into which a small-diameter optical fiber for launching light and the small-diameter optical fiber for receiving light are inserted, through the lymph vessel to identify the presence or absence of the metastasis of cancer cells even before the surgery of cancer or during prognosis.

The invention relates to a healthcare product beverage. The beverage comprises forsythia leaf extract and traditional Chinese medicines mixed extracting liquid of endive, umbellate rock jasmine, radix scutellariae. The healthcare beverage has the functions of clearing away heat and toxic materials, resisting against bacteria, diminishing inflammation, resisting against oxidation, preventing corrosion, inhibiting bacteria and protecting the liver. The beverage can be used for auxiliary therapy after cancer surgery. The technical problem to be solved is to provide the forsythia leaf extract beverage which has the effects of clearing away heat and toxic materials, resisting against inflammation, inhibiting bacteria and resisting against viruses, and can relieve diseases such as acute pharyngitis and amygdalitis. The adopted technical scheme is that the functional ingredients include forsythia leaf extract and traditional Chinese medicines mixed extracting liquid of endive, umbellate rock jasmine, radix scutellariae. The forsythia leaf extract accounts for 0.3-6% of the total weight of the forsythia leaf beverage; the traditional Chinese medicines mixed extract accounts for 2-4% of the total weight of the forsythia leaf beverage. The forsythia leaf beverage can be widely applied to the technical field of the forsythia leaf beverage.

The invention provides a device for cancer surgery fluorescence guiding and residual cancer tracing and clearing. The device is formed by combination of a host, an image lighting and acquiring unit and a photodynamics therapy irradiator, wherein the host is provided with a program controller, a fluorescence-reflected light image processor, an image displayer and an image lighting and therapy lighting source. Surgical navigation can be conducted after a proper amount of target nanometer photosensitizer is injected into the body of a patient, residual cancer tracing is conducted in surgery, and key information is provided for precise treatment of cancer patients. Peripheral occult cancer and residual cancer in blood can be detected, tumor cells are killed selectively, photodynamics therapy which hardly causes damage to healthy tissue is adopted, and residual cancer is eradicated. In this way, radiotherapy and chemotherapy quite harmful to health do not need to be adopted to prevent canceration, recurrence and metastasis after cancer surgery treatment, the survival rate of cancer patients can be increased greatly, and the living quality of cancer patients in the recovery period can be improved greatly.

One or more aqueous, near infrared emitting, high yield, highly photoluminescent, stable quantum dots conjugated to one or more biomarkers specific moieties. The conjugated quantum dots have an enhanced detection sensitivity and selectivity and may be formed using a novel and efficient method for conjugating one or more biomarker specific moieties to the quantum dots. The invention is further directed to a method for using the conjugated quantum dots for cancer detection in the margin of excised tissue.

The invention relates to a pharmaceutical composition for enema treatment of abdominal distension after a colon cancer surgery, and application thereof. The pharmaceutical composition is prepared from the following Chinese herbal medicine raw materials in parts by weight: 15-30 parts of tangerine leaves, 12-24 parts of semen litchi, 12-24 parts of summer purslane, 12-24 parts of herba epimedii, 8-16 parts of pseudo-ginseng, 8-16 parts of elecampane, 5-10 parts of monthly rose, 5-10 parts of peach kernel, 5-10 parts of coptis chinensis and 30-60 parts of semen coicis. The pharmaceutical composition disclosed by the invention has the functions of stimulating intestinal tubes and increasing gastrointestinal propulsion, and is simple and feasible, the creep volume and the pushing function of an intestinal tract are significantly increased, the incidence rate of abdominal distension can be effectively reduced, the peristalsis recovery time is shortened, and the treatment time is also reduced.

The present subject matter relates to fluorescent compounds that have aggregation-induced emission (AIE) characteristics. The compounds exhibit boosted fluorescence, photoacoustic (PA) properties, and Raman properties. The compounds, in nanoparticle form, can generate high fluorescence, PA, and Raman signals in aqueous environments. The compounds can be used to identify tumors at different surgical stages and improve cancer surgery outcomes.

The invention relates to a Chinese material medical preparation for treating esophagus cancer and gastric cancer of the digestive system, raw materials of which are made by the following components according to the weight account: 10-30 portions of night shade, 15-30 portions of woody nightshade, 15-120 portions of Chinese actinidia root, 10-60 portions of marsdenia tenacissima, 3-15 portions of airpotato yam, 15-60 portions of sticktight, 3-9 portions of trifoliate orange, 3-9 portions of endothelium corneum gigeriae galli, 10-30 portions of malt, 10-30 portions of rhizoma imperatae and 15-30 portions of Chinese Lobelia. The Chinese material medical preparation is taken by hundreds of patients for more than ten years so as to prove that the treatment effect is better without toxic side effect, and the effects of improving immunizing power, promoting digestive absorption and preventing canceration from dispersing are obtained by the patients suffered from the esophagus cancer and the gastric cancer, and has remarkable getting-well effect to especially cancer postoperative patients.

The present invention relates to a novel model for predicting a prognosis capable of predicting the prognosis of gastric cancer, and more specifically, to manufacturing a prediction model for predicting a clinical result after a resection during gastric cancer surgery through genetic mutation comparative analysis.

The present invention relates to a cancer operating room failure rate analysis device, comprising: a high-angle photographing device including a mobile cradle head capable of being disposed on the topof a cancer operating room to perform photographing operation on the internal environment of the cancer operating room to obtain and output a corresponding internal image of the cancer operating room; a fault notification device, used for receiving the fault rate, sending out an overall replacement instruction when the fault rate exceeds a preset percentage threshold value, and sending out a usemaintaining instruction when the fault rate does not exceed the preset percentage threshold value; a fault notification device, comprising an LED display screen arranged on the mobile holder and a voice playing chip arranged on the mobile holder. The failure rate analysis device for the cancer operating room is simple to operate and convenient for reference. As the visual analysis mode is adoptedto effectively detect the failure rate, the original rough manual detection mode is replaced, and the detection speed and precision are improved.

The invention relates to a healthcare product beverage. The beverage comprises forsythia leaf extract and traditional Chinese medicines mixed extracting liquid of endive, umbellate rock jasmine, radix scutellariae. The healthcare beverage has the functions of clearing away heat and toxic materials, resisting against bacteria, diminishing inflammation, resisting against oxidation, preventing corrosion, inhibiting bacteria and protecting the liver. The beverage can be used for auxiliary therapy after cancer surgery. The technical problem to be solved is to provide the forsythia leaf extract beverage which has the effects of clearing away heat and toxic materials, resisting against inflammation, inhibiting bacteria and resisting against viruses, and can relieve diseases such as acute pharyngitis and amygdalitis. The adopted technical scheme is that the functional ingredients include forsythia leaf extract and traditional Chinese medicines mixed extracting liquid of endive, umbellate rock jasmine, radix scutellariae. The forsythia leaf extract accounts for 0.3-6% of the total weight of the forsythia leaf beverage; the traditional Chinese medicines mixed extract accounts for 2-4% of the total weight of the forsythia leaf beverage. The forsythia leaf beverage can be widely applied to the technical field of the forsythia leaf beverage.

The present subject matter relates to fluorescent compounds that have aggregation-induced emission (AIE) characteristics and exhibit near infrared absorption. Compositions including the present compounds can include a corannulene-modified polyethylene glycol encapsulation matrix. The compositions can be in nanoparticle form. Encapsulating the AIE compounds within a corannulene matrix provides intraparticle rigidity and restricts intramolecular rotation of the encapsulated AIE compound, which results in enhanced fluorescence and ROS generation capacity of the compositions in vivo. Accordingly,the compositions can be useful in NIR imaging-guided cancer surgery and photodynamic cancer therapy.

The present invention discloses a ginger pop taro bean curd, which is prepared from the following raw materials by weight: 100-110 parts of soybean, 20-30 parts of taro, 0.8-1 part of hypericum japonicum thunb, 1-1.2 parts of kirilow rhodiola root and rhizome, 0.8-1 part of curcuma, 1-2 parts of lotus pedicle (b), 3-4 parts of crab meat ( / b), 3-4 parts of blood glutinous, 2-3 parts of undaria pinnitafida, 1-1.1 parts of purple cabbage, 0.9-1.1 parts of robiniae, 3-4 parts of bananas, 2-3 parts of fresh ginger, 2-3 parts of gynura divaricata, 1-2 parts of corn oil, 4-5 parts of red bean flour, 4-5 parts of duck meat, 1-2 parts of brine and 4-5 parts of nutritional additives. The bean curd in the present invention has strong fragrance. The added taro contains a plurality of trace elements that can enhance the body's immune function. The bean curd can be used as staple food of regular medicated diet for prevention and treatment of cancer, has good assistant effect for the rehabilitation process after cancer surgery or postoperative radiotherapy and chemotherapy, and has functions of teeth cleaning, dental caries preventing and teeth protecting. In addition, in the production process of the present invention, a plurality of Chinese herbs are added to provide efficacy of strengthening spleen and stomach, regulating middle energizer qi, dispelling wind-evil, activating blood circulation, removing summer-heat and eliminating dampness.

The present invention is concerned with an in vitro method of diagnosing cancer in a tissue sample, wherein said tissue sample is obtained from a patient undergoing cancer surgery. The method described herein is based on a hyperpolarized marker, which is contacted with the tissue sample, and an NMR spectrum and / or an MR image obtained of the tissue sample after having been contacted with the hyperpolarized marker.

The present application provides an anticancer composition comprising an anticancer active ingredient and a pharmaceutically acceptable carrier, wherein the anticancer active ingredient comprises collagenase II, collagenase IV or a combination thereof, preferably collagenase II. The present application also provides the use of the anticancer composition in the preparation of a medicament for the treatment of cancer. The anticancer composition of the present invention is suitable for intratumoral injection or implantation, peritumoral injection or implantation, and intratumoral injection or implantation after cancer surgery. The anticancer composition can be made into various pharmaceutical dosage forms, preferably injection.

The inventors found that postsurgical recurrence and / or metastasis of cancer is suppressed by administering a beta-blocker to a cancer patient during a perioperative period of cancer surgery. Accordingly, the disclosure provides an agent for suppressing recurrence and / or metastasis of cancer, comprising a beta-blocker and being administered during a perioperative period of cancer surgery.

An anticancer medical composition for treating cancers, leukemia, hepatitis, hepatocirrhosis, etc is proportionally prepared from gynostemma pentaphyllum or its extract, cordyceps or its extract, cantharidin or its derivative or its analog, and / or toad venom or its extract. It can be used the relative medicine by mixing it with the pharmacologically acceptable auxiliaries.

The present invention relates to the technical field of specimen collection devices, more specifically, to a specimen collection equipment for clinical colon cancer surgery in general surgery, which includes a specimen collection cylinder, an overturned cylinder cover, a cylinder cover opening and closing mechanism, a specimen supporting mechanism and a base seat; the specimen collection tube is connected to the base; one end of the lid opening and closing mechanism is connected to the base, and the other end of the lid opening and closing mechanism is connected to the flipping lid , the middle part of the lid opening and closing mechanism is connected to the specimen collection cylinder; the specimen holding mechanism is connected to the flipping cylinder lid. The invention not only can be used for storing the colon specimen, but also can change the structure to display the colon specimen, so that medical personnel can study the colon specimen from multiple directions.

The invention discloses a tumor protection sleeve for colon cancer surgery. The tumor protection sleeve comprises an equipment device body, medical protection cloth and a first connecting side plate, a first bonding block is tightly sewn to one side of the outer wall of the medical protection cloth, a second bonding block is tightly sewn to the other side of the outer wall of the medical protection cloth, and a smooth surface wall is fixedly connected to the surface of the medical protection cloth. When the medical protection cloth is laid and used, the medical protection cloth is attached to the skin through the first bonding block and the second bonding block on the two sides for bonding, the surface has viscidity, and when the medical protection cloth is used, the medical protection cloth is unfolded from the medical protection cloth for use; and the surface of the first bonding block and the surface of the second bonding block are each provided with a layer of protective film, when the medical protection cloth needs to be used, the protective films on the surfaces of the first bonding block and the second bonding block are opened for use, the situation that the medical protection cloth slips off or automatically deviates can be conveniently avoided when the medical protection cloth is laid, and blood in the operation process rapidly slips off in combination with the arrangement of the smooth surface wall.

A targeted drug delivery device comprises a brush for use in delivery of one or more therapeutic agents during surgical procedures, including but not limited to, heart, chest, abdominal, brain, limb, vascular, eye, organ transplantation surgery or cancer surgical treatment. The therapeutic agent is selected from the group consisting of genetically engineered vectors or cells, proteins, stem cells, small molecule pharmaceuticals, drugs or biologics. Methods of treating diseases comprising delivering at least one therapeutic agent to a patient's organs or tissues using any one of the targeted drug delivery devices are disclosed.